Shared Medical Systems Corp.
This article was originally published in The Gray Sheet
Executive SummaryAnti-takeover shareholder rights plan is amended to delete all provisions requiring certain actions under the plan to be authorized by "continuing directors," the firm announces March 20. The order was taken to "conform the terms of the plan to recent decisions by the Delaware courts." Rebuffed suitor Eclipsys, which launched an unsolicited $2 bil. merger proposal March 2, had filed suit in Delaware Chancery Court challenging the legality of the "continuing director provision" of SMS' "poison pill" shareholder rights plan (1"The Gray Sheet" March 13, p. 14). SMS has scheduled its annual shareholders meeting for June 9, instead of May 16 as previously anticipated, to allow more time for the firm to evaluate various strategic alternatives
You may also be interested in...
Biogen value-based contract with UPMC Health Plan ties payments to patient-reported outcomes for Tecfidera and Avonex. The company may seek something similar for Vumerity.
As interest in immune/inflammatory disease increases and savings achieved dip, payer focus on patient-reported outcomes for contracts reflects shift in focus, Avalere survey suggests.